Literature DB >> 24122841

Opportunities and challenges of combined effect measures based on prioritized outcomes.

Geraldine Rauch1, Antje Jahn-Eimermacher, Werner Brannath, Meinhard Kieser.   

Abstract

Many authors have proposed different approaches to combine multiple endpoints in a univariate outcome measure in the literature. In case of binary or time-to-event variables, composite endpoints, which combine several event types within a single event or time-to-first-event analysis are often used to assess the overall treatment effect. A main drawback of this approach is that the interpretation of the composite effect can be difficult as a negative effect in one component can be masked by a positive effect in another. Recently, some authors proposed more general approaches based on a priority ranking of outcomes, which moreover allow to combine outcome variables of different scale levels. These new combined effect measures assign a higher impact to more important endpoints, which is meant to simplify the interpretation of results. Whereas statistical tests and models for binary and time-to-event variables are well understood, the latter methods have not been investigated in detail so far. In this paper, we will investigate the statistical properties of prioritized combined outcome measures. We will perform a systematical comparison to standard composite measures, such as the all-cause hazard ratio in case of time-to-event variables or the absolute rate difference in case of binary variables, to derive recommendations for different clinical trial scenarios. We will discuss extensions and modifications of the new effect measures, which simplify the clinical interpretation. Moreover, we propose a new method on how to combine the classical composite approach with a priority ranking of outcomes using a multiple testing strategy based on the closed test procedure.
Copyright © 2013 John Wiley & Sons, Ltd.

Keywords:  composite endpoints; multiple testing; prioritized outcomes; time-to-event data; weighting procedure

Mesh:

Year:  2013        PMID: 24122841     DOI: 10.1002/sim.6010

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  12 in total

1.  Large sample inference for a win ratio analysis of a composite outcome based on prioritized components.

Authors:  Ionut Bebu; John M Lachin
Journal:  Biostatistics       Date:  2015-09-08       Impact factor: 5.899

2.  The inverse-probability-of-censoring weighting (IPCW) adjusted win ratio statistic: an unbiased estimator in the presence of independent censoring.

Authors:  Gaohong Dong; Lu Mao; Bo Huang; Margaret Gamalo-Siebers; Jiuzhou Wang; GuangLei Yu; David C Hoaglin
Journal:  J Biopharm Stat       Date:  2020-06-17       Impact factor: 1.051

3.  Opportunities and challenges of clinical trials in cardiology using composite primary endpoints.

Authors:  Geraldine Rauch; Bernhard Rauch; Svenja Schüler; Meinhard Kieser
Journal:  World J Cardiol       Date:  2015-01-26

Review 4.  Biomarker validation: common data analysis concerns.

Authors:  Joe E Ensor
Journal:  Oncologist       Date:  2014-07-07

Review 5.  Establishing an evaluation mode with multiple primary outcomes based on combination of diseases and symptoms in TCM clinical trials.

Authors:  Jing Hu; Shuo Liu; Weihong Liu; Huina Zhang; Jing Chen; Hongcai Shang
Journal:  Ann Transl Med       Date:  2017-11

6.  Statistical models for composite endpoints of death and non-fatal events: a review.

Authors:  Lu Mao; KyungMann Kim
Journal:  Stat Biopharm Res       Date:  2021-07-06       Impact factor: 1.586

7.  A framework for considering the risk-benefit trade-off in designing noninferiority trials using composite outcome approaches.

Authors:  Grace Montepiedra; Ritesh Ramchandani; Sachiko Miyahara; Soyeon Kim
Journal:  Stat Med       Date:  2020-10-26       Impact factor: 2.373

8.  Applying a Risk-benefit Analysis to Outcomes in Tuberculosis Clinical Trials.

Authors:  Sachiko Miyahara; Ritesh Ramchandani; Soyeon Kim; Scott R Evans; Amita Gupta; Susan Swindells; Richard E Chaisson; Grace Montepiedra
Journal:  Clin Infect Dis       Date:  2020-02-03       Impact factor: 9.079

9.  Totality of outcomes: A different paradigm in assessing interventions for treatment of tuberculosis.

Authors:  Grace Montepiedra; Courtney M Yuen; Michael L Rich; Scott R Evans
Journal:  J Clin Tuberc Other Mycobact Dis       Date:  2016-08

10.  Weighted analysis of composite endpoints with simultaneous inference for flexible weight constraints.

Authors:  Anh Nguyen Duc; Marcel Wolbers
Journal:  Stat Med       Date:  2016-10-26       Impact factor: 2.373

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.